Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,622 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02110082 | Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer | completed | Phase 1 | 66 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00004095 | Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 38 | Northwestern UniversityOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00940758 | Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy | completed | Phase 1 | 18 | PharmaEngineINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01047293 | RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 47 | University of UtahOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT02156557 | Study of KCC Peptide Application in the Colon(KCC 1B) | completed | Phase 1 | 45 | Danielle Kim TurgeonOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT01150877 | High Dose Vitamin D Study | completed | Phase 1 / Phase 2 | 40 | University of British ColumbiaOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01207895 | Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer | completed | Phase 1 | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01469611 | A Trial of JX-594 in Refractory Colorectal Carcinoma | completed | Phase 1 | 15 | Samsung Medical CenterOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT01304602 | A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer | completed | Phase 1 | 20 | University of Kansas Medical CenterOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT02236884 | The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer | completed | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00449137 | Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment | completed | Phase 1 | 13 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT01395667 | Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX | completed | Phase 1 | 15 | National Taiwan University HospitalOTHER | 1 | Nov 10, 2016 | clinicaltrials |
| NCT01148758 | A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer | completed | Phase 1 | 7 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT02033551 | A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 | 47 | AbbVieINDUSTRY | 3 | Sep 27, 2016 | clinicaltrials |
| NCT01376453 | Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer | completed | Phase 1 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 12, 2016 | clinicaltrials |
| NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | completed | Phase 1 | 48 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 8, 2016 | clinicaltrials |
| NCT00496509 | Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 26, 2016 | clinicaltrials |
| NCT00499850 | Phase I FOLFOX Combination | completed | Phase 1 | 18 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01086267 | Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 17 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 27, 2016 | clinicaltrials |
| NCT01115790 | A Phase 1 Study in Participants With Advanced Cancer | completed | Phase 1 | 150 | Eli Lilly and CompanyINDUSTRY | 1 | May 10, 2016 | clinicaltrials |
| NCT01675128 | ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2016 | clinicaltrials |
| NCT00563316 | Effect of Panitumumab on the Pharmacokinetics of Irinotecan | completed | Phase 1 | 28 | AmgenINDUSTRY | 2 | Apr 12, 2016 | clinicaltrials |
| NCT00558051 | Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 15 | Pawel KalinskiOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT00353262 | A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer. | completed | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT01554969 | Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer | completed | Phase 1 | 16 | Emory UniversityOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00920868 | XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib(XAD) | completed | Phase 1 | 22 | Herbert Hurwitz, MDOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT01203969 | Safety and Efficacy of Single Port Laparoscopic Surgery in Colon Cancer | completed | Phase 1 | 62 | Kyunghee University Medical CenterOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT02020291 | Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer | completed | Phase 1 | 31 | WntResearch ABINDUSTRY | 1 | Feb 2, 2016 | clinicaltrials |
| NCT00876954 | Preoperative Hyperthermia in Major Abdominal Surgery Patients | completed | Phase 1 / Phase 2 | 20 | Medical University of ViennaOTHER | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01791309 | Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer | completed | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT02489916 | Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 47 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00574977 | Safety Study of Modified Vaccinia Virus to Cancer | completed | Phase 1 | 26 | David BartlettOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00581815 | Spectroscopy With Surface Coils and Decoupling | completed | Phase 1 | 582 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00594984 | Phase I/II Combination With Irinotecan- Erbitux | completed | Phase 1 / Phase 2 | 38 | Bristol-Myers SquibbINDUSTRY | 7 | Nov 4, 2015 | clinicaltrials |
| NCT00207155 | An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer | completed | Phase 1 | 110 | Eli Lilly and CompanyINDUSTRY | 3 | Oct 28, 2015 | clinicaltrials |
| NCT01516489 | Improving Fecal Occult Blood Test Completion Rates Among Veterans | completed | Phase 1 / Phase 2 | 1,549 | Corporal Michael J. Crescenz VA Medical CenterFED | 1 | Oct 26, 2015 | clinicaltrials |
| NCT01164215 | Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy | completed | Phase 1 | 76 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01461148 | Vaccination Against MSI Colorectal Cancer | completed | Phase 1 / Phase 2 | 22 | Oryx GmbH & Co. KGINDUSTRY | 1 | Jun 23, 2015 | clinicaltrials |
| NCT01205022 | Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01294826 | Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 1 | 20 | Swedish Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01110941 | Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China(SCI-101) | completed | Phase 1 / Phase 2 | 20 | Shen LinOTHER | 1 | May 19, 2015 | clinicaltrials |
| NCT00522665 | Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer | completed | Phase 1 / Phase 2 | 41 | Hoosier Cancer Research NetworkOTHER | 1 | May 15, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Apr 19, 2017source: clinicaltrials